<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115635</url>
  </required_header>
  <id_info>
    <org_study_id>UR0416</org_study_id>
    <secondary_id>EudraCT number: 2004-002353-31</secondary_id>
    <nct_id>NCT00115635</nct_id>
  </id_info>
  <brief_title>Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer</brief_title>
  <official_title>A Phase I/II Study With Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the optimal dose of the combination of docetaxel and
      gemcitabine in patients with hormone refractory prostate cancer, and evaluate this dose with
      respect to efficacy and toxicity in a phase II trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-specific antigen (PSA) response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified adenocarcinoma of the prostate.

          -  Hormone refractory prostate cancer (HRPC) defined as progression during previous
             anti-hormone treatment. Patients must have been off previous anti-androgen therapy for
             more than 4 weeks.

          -  Stage IV disease (verified by imaging or clinical examination).

          -  PSA &gt; 10 microgram/l.

          -  PSA progression defined as a &gt; 25% increase between two independent measurements
             performed with a 1-month interval or more after discontinuation of anti-androgen
             treatment.

          -  Castrate level of testosterone (&lt; 50 ng).

          -  No previous oestrogen or steroid as metastatic prostate cancer treatment.

          -  Satisfactory hepatic function in the form of total bilirubin ≤ UNL (upper normal
             limit), ASAT/ALAT ≤ 2.5 x UNL, alkaline phosphatase ≤ 5 x UNL.

          -  Satisfactory renal function, defined as serum creatinine ≤ 1.5 x UNL.

          -  Satisfactory haematologic function defined as ANC &gt;1.5 x 10^9/l, leucocytes &gt;3.0 x
             10^9/l, thrombocytes ≥ 100 x 10^9/l, haemoglobin &gt; 7 mmol/l

          -  ECOG performance status ≤ 2.

          -  Life expectancy &gt; 3 months.

          -  Patient must be able to adhere to protocol requirements.

          -  Written informed consent.

          -  &gt; 18 years of age.

        Exclusion Criteria:

          -  Previous prostate cancer treatment with oestrogens or steroid hormones.

          -  Previous chemotherapy.

          -  Previous treatment with systemic radioactive isotopes.

          -  Bisphosphonate treatment (concomitant).

          -  Radiation therapy covering more than 25% of the bone marrow producing area.

          -  Other serious coincidental and/or concomitant medical condition.

          -  Symptomatic cerebral metastases.

          -  Other previous or current malignant disease, excluding *adequately treated and cured
             planocellular skin carcinoma; or *other cancer assessed to carry minimal risk of
             recurrence.

          -  ECOG performance status &gt; 2.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Sengelov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Oncology, Herlev Hospital, 2730 Herlev, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Oncology, 54B1, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2005</study_first_submitted>
  <study_first_submitted_qc>June 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2005</study_first_posted>
  <last_update_submitted>October 1, 2007</last_update_submitted>
  <last_update_submitted_qc>October 1, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2007</last_update_posted>
  <keyword>Hormonal refractory, chemotherapy, docetaxel, gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

